AstraZeneca Pharma India Appoints New Managing Director
AstraZeneca Pharma India Ltd has appointed Praveen Rao Akkinepally as its new Managing Director, effective July 1, for an initial term of three years. Sanjeev Kumar Panchal, the current Managing Director, is stepping down to take on a global role within the AstraZeneca Group in the United States.
02Jun 25
AstraZeneca Pharma India Reports Robust Q4 Performance, Stock Surges 8%
AstraZeneca Pharma India delivered impressive Q4 financial results. Net profit increased by 47.70% to ₹58.20 crore, while revenue grew 25.40% to ₹480.40 crore. EBITDA rose 75.00% to ₹86.00 crore, with EBITDA margin expanding by 500 basis points to 17.96%. The company's stock price surged 8.13% following the announcement, reflecting positive market sentiment.
30May 25
AstraZeneca Pharma India Reports Robust Q4 Performance with 47.7% Profit Surge
AstraZeneca Pharma India Limited reported strong Q4 results with net profit up 47.7% YoY to ₹58.20 crore. Revenue increased 25.4% to ₹480.40 crore, while EBITDA surged 74.7% to ₹86.30 crore. The company declared a final dividend of ₹32.00 per share for FY25. Annual results for FY 2024 showed revenue growth of 29.27% and net profit increase of 62.64%.
30May 25
AstraZeneca Pharma India Announces ₹32 Per Share Dividend
AstraZeneca Pharma India Limited has announced a dividend of ₹32 per share for its shareholders. The company, a subsidiary of AstraZeneca PLC, is involved in manufacturing, distributing, and marketing pharmaceutical products in India. Specific details about the dividend's timing and nature were not provided in the announcement.
30May 25
AstraZeneca Pharma India Secures Approval for Benralizumab Import
AstraZeneca Pharma India has received approval from the Government of India to import, sell, and distribute Benralizumab, a 30 mg/mL solution for injection. This approval allows the company to expand its product portfolio in the Indian pharmaceutical market, particularly in the respiratory disease segment. Benralizumab is primarily used for treating severe eosinophilic asthma.
29May 25
AstraZeneca India Secures Approval to Import Osimertinib Tablets
AstraZeneca India has received approval from the Central Drugs Standard Control Organization (CDSCO) to import, sell, and distribute Osimertinib tablets in India. Osimertinib is a third-generation EGFR tyrosine kinase inhibitor used to treat certain types of non-small cell lung cancer. This approval expands AstraZeneca's oncology portfolio in India and could potentially benefit a significant number of lung cancer patients in the country.
08May 25
AstraZeneca Pharma India Expands Enhertu® Approval for HER2-Low Breast Cancer
AstraZeneca Pharma India has received approval to import and market Enhertu® for HER2-low and ultralow metastatic breast cancer in India, expanding its oncology portfolio. This approval addresses a significant unmet need in breast cancer treatment, offering new hope for patients with limited options. While the financial impact is yet to be determined, this development could potentially increase AstraZeneca's market share in India's oncology sector.
07Apr 25
AstraZeneca Pharma India Secures Approval for Expanded Use of Osimertinib Tablets
AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation (CDSCO) for an additional indication of its Osimertinib Tablets (Tagrisso) in 40 mg and 80 mg strengths. The company is now permitted to import, sell, and distribute the drug for this new indication. Osimertinib is primarily used to treat certain types of non-small cell lung cancer, and this expanded approval could potentially increase AstraZeneca's market reach and revenue streams in India.
04Apr 25
AstraZeneca Pharma India Secures Approval for Expanded Use of Cancer Drug Tagrisso
AstraZeneca Pharma India has received regulatory approval from CDSCO for an additional indication of Tagrisso (Osimertinib). The drug can now be used in combination with chemotherapy as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. The company awaits further statutory approvals before launch.
28Mar 25
AstraZeneca Pharma India to Discontinue Imdur Tablets by 2025
AstraZeneca Pharma India Limited has announced the discontinuation of Imdur tablets, a medication for preventing angina in coronary artery disease patients, effective April 1, 2025. This decision will impact patients currently using the drug, requiring them to seek alternative treatments. Healthcare providers will need to adjust their prescribing practices. The nearly two-year notice period allows for a smooth transition for all stakeholders.